Lexicon beats with loss <$0.01 per share and revenue $21.1M vs $8.7M expected

 

Lexicon Pharmaceuticals beats Q1 2026 estimates with loss <$0.01 per share and revenue $21.1M vs $8.7M expected

• Lexicon reported Q1 2026 net loss of $1 million, complementing loss of less than $0.01 per share.
• Q1 2026 revenue of $21.1M was driven by milestones from Novo Nordisk under existing collaboration.
• Novo Nordisk has initiated a Phase 1 trial of obesity candidate LX9851 under its collaboration with Lexicon.
• Lexicon plans a mid-2026 ZYNQUISTA NDA resubmission as part of its updated pipeline strategy.

https://finviz.com/quote?t=LXRX&p=d